Translating Microbiome R&D into Improved Healthcare Outcomes & Commercial Potential

While Infant Bacterial Therapeutics pushed towards pharmaceutical registration, MRM Health pioneers lived microbial consortium therapies for IBD and Microbiotica accelerated into the clinic with assets for advanced melanoma and UC. The microbiome biotech pipeline was overflowing with compelling data, increasingly validating the transformative potential of microbiome-based therapies across diverse disease areas.

With the first LBP approvals on the horizon, but financial pressures threatening to slow progress, the 9^th Microbiome Movement Summit Europe returned to Barcelona in January as the essential industry hub for R&D and business leaders determined to push the field forward.

The Summit explored the latest advances in microbiome science, where innovative biotechs were uncovering new microbial targets, deciphering mechanisms of action and harnessing state-of-the-art analytical tools to uncover the microbiome’s role in disease. Attendees engaged with investors and C-level leaders as our producers strategised how to bring big pharma back into the fold of emerging microbial modalities.